Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile - GlobalData Financial Mergers and Acquisitions Intelligence
Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile
Published Oct 18, 2016
68 pages — Published Oct 18, 2016
Price US$ 250.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Cerus Corporation (Cerus) is a biomedical products manufacturing company which develops and commercializes Intercept Blood System for blood safety. The company has rights of Intercept for three blood components, namely, platelets, red blood cells and plasma. The system is designed to target and inactivate blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells (WBC) included in donated blood components intended for transfusion.

Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical Equipment eTrack deals database, and primary and secondary research.


Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.


Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself w

  
Source:
Document ID
GDME26394D
Country
Industry
Ticker
Company
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents24
  List of Tables41
  List of Figures51
Cerus Corporation, Medical Equipment, Deals By Year, 2010 to YTD 201652
Cerus Corporation, Medical Equipment Deals By Type, 2010 to YTD 201671
Cerus Corporation, Medical Equipment, Deals By Region, 2010 to YTD 201681
Cerus Corporation, Medical Equipment, Deals By Market, 2010 to YTD 201691
Cerus Corporation, Medical Equipment, Deals Summary, 2010 to YTD 2016101
Cerus Corporation, Medical Equipment, Deal Details1115
  Partnerships111
    Cerus Terminates Licensing Agreement With BioOne111
    Cerus Enters into Agreement with Haemonetics121
    Cerus Enters into Agreement with Kawasumi Labs to Develop Intercept Platelets Kits in Japan131
    Cerus Enters into Co-Marketing Agreement with Biomedica Foscama141
    Cerus Enters Into Distribution Agreement With American Red Cross For Intercept Plasma151
    Cerus Enters Into Distribution Agreement With Blood Systems For Intercept Plasma161
    Cerus Enters Into Distribution Agreement With Ilex Biotech171
    Cerus Enters Into Agreement With CSL181
  Equity Offering191
    Cerus Plans to Raise USD70 Million in Public Offering of Shares191
    Cerus Prices Public Offering of Shares for USD70 Million202
    Cerus Completes Public Offering Of Shares For US$40.3 Million222
    Cerus Completes Underwritten Public Offering Of US$21 Million242
Cerus Corporation - Key Competitors261
Key Employees271
Locations And Subsidiaries281
  Head Office281
  Other Locations &Subsidiaries281
Recent Developments291
Financial Announcements291
Aug 04, 2016: Cerus Reports Second Quarter 2016 Results292
May 03, 2016: Cerus Corporation Reports First Quarter 2016 Results312
Mar 08, 2016: Cerus Reports Fourth Quarter and Year End 2015 Results332
Nov 05, 2015: Cerus Reports Third Quarter 2015 Results352
Aug 06, 2015: Cerus Reports Second Quarter 2015 Results372
May 05, 2015: Cerus Reports First Quarter 2015 Results392
Feb 26, 2015: Cerus Reports Fourth Quarter and Year-End 2014 Results412
Corporate Communications431
Aug 09, 2016: Vivek Jayaraman Appointed as Cerus Corporation s Chief Commercial Officer431
Jan 11, 2016: Cerus Appoints New Leadership for Europe, Middle East and Africa Region441
Jun 08, 2015: Richard J. Benjamin, MD PhD Appointed as Cerus Corporation s New Chief Medical Officer451
Product News461
Mar 16, 2016: Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma461
Mar 15, 2016: Cerus Announces the Inclusion of Pathogen Reduction Technology in FDA s Revised Guidance Document on Bacterial Safety Standards for Platelets471
Mar 09, 2016: Blood Centers of America Selects Cerus as its Supply Partner for Pathogen Reduction Technology481
Feb 09, 2016: Cerus Enters Multi-Year Agreement with the American Red Cross for the Use of INTERCEPT Platelets and Plasma491
Jan 14, 2016: AABB Authorizes Use of the INTERCEPT Blood System for Platelets to Reduce the Risk of Transfusion-Associated Graft Versus Host Disease501
Jan 05, 2016: Cerus Announces Agreement with Blood Systems for the Use of INTERCEPT Platelets and Plasma511
Dec 10, 2015: Cerus Announces Agreement with the National Transfusiology Center of Mongolia for the Use of INTERCEPT Platelets and Plasma521
Dec 07, 2015: Cerus and Shepeard Community Blood Center Enter into Agreement for the Use of INTERCEPT Platelets and Plasma531
Nov 02, 2015: Cerus Announces CMS Issuance of Permanent P-Codes for Outpatient Hospital Billing of Pathogen-Reduced Platelets and Plasma541
Apr 27, 2015: Cerus To Present At AABB Symposium On Pathogen-Reduced Components551
Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets561
Feb 27, 2015: Cerus Signs INTERCEPT Platelet Agreement With Sweden s Largest Blood Product Supplier571
Jan 28, 2015: Ash Stevens to Manufacture Amotosalen Active Pharmaceutical Ingredient for Cerus' INTERCEPT Blood System581
Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint591
Product Approvals601
Mar 16, 2016: Cerus Receives FDA Approval for Use of the INTERCEPT Blood System for Platelets Suspended in 100% Plasma601
Clinical Trials611
Mar 16, 2015: First Patient Enrolled In Cerus' True Study With The American Red Cross To Address Chikungunya And Dengue Blood Safety Risks With Pathogen Reduced Platelets611
Jan 05, 2015: Cerus Reports EU Phase 3 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint621
Other Significant Developments631
Oct 10, 2016: Cerus Announces that Hemolife Fundaci n Banco Nacional de Sangre Has Entered into Routine Use of the INTERCEPT Blood System631
Jul 11, 2016: Cerus Provides an Update on Adoption by Blood Centers of America Members for the INTERCEPT Blood System for Platelets and Plasma642
Oct 21, 2015: Cerus Announces New Agreement With Fresenius Kabi for the Production of INTERCEPT Blood System Kits661
Jul 13, 2015: Cerus and Bonfils Blood Center Enter Into Agreement for the Use of INTERCEPT Platelets and Plasma671
Appendix681
  Methodology681
  About GlobalData681
  Contact Us681
  Disclaimer681

Table Of Contents

About the Author


Cite this Report

  
MLA:
GlobalData Financial Mergers and Acquisitions Intelligence. "Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile" Oct 18, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Cerus-Corporation-CERS-Medical-Equipment-Deals-and-Alliances-Profile-2148-5556>
  
APA:
GlobalData Financial Mergers and Acquisitions Intelligence. (2016). Cerus Corporation (CERS) - Medical Equipment - Deals and Alliances Profile Oct 18, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/GlobalData-Financial-Mergers-and-Acquisitions-Intelligence/Cerus-Corporation-CERS-Medical-Equipment-Deals-and-Alliances-Profile-2148-5556>
  
US$ 250.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research